실시간
Roche MediaRoche signs $2.3bn blood cancer drug agreement with Nurix Therapeutics - Pharmaceutical TechnologyEndpoints NewsIncyte to buy bleeding disorder biotech Vega Therapeutics in $1.25B upfront dealEndpoints NewsTakeda says it expects to take $2.5B hit after Amitiza antitrust verdict, with plans to appealEndpoints NewsNurix to work with Roche on BTK degrader in deal worth up to $2.3BFierceBiotechADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 updateFierceBiotechRoche bets $700M upfront on Nurix’s late-phase BTK degrader to tee up Lilly showdownBioPharma DiveInnovation alone is no longer enough in biopharmaBioPharma DivePrecision under pressure: Logistic solutions for nuclear medicine scalabilityLonza NewsLonza and Stipple Bio strike licensing deal for precision oncology ADCs - BioXconomyRoche MediaRoche Korea picks 4 Korean biotech firms for K-Swiss BioPass program - koreabiomed.comFierceBiotechCould engaging the immune system improve AML outcomes?FierceBiotechWhy AI is changing clinical development
Endpoints News 2026년 1월 22일

Another biopharma tried buying Amicus before BioMarin's $4.8B deal

Another biopharma tried buying Amicus before BioMarin's $4.8B deal

원문
본문을 이용할 수 없습니다. 원본 출처를 확인하세요.